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Abstract
Aims/hypothesis The intestine is the main site for glucose ab-
sorption and it has been suggested that it exhibits insulin re-
sistance. Bariatric surgery has been shown to reverse insulin
resistance and type 2 diabetes, but its effects on human intes-
tinal metabolism are unknown. Our aim was to evaluate the
effects of insulin on intestinal glucose metabolism before and
after bariatric surgery.
Methods Twenty-one morbidly obese individuals undergoing
bariatric surgery and ten age-matched healthy individuals were
recruited and intestinal and skeletal muscle glucose uptake (GU)
was measured using [18F]fluoro-2-deoxyglucose and positron
emission tomography at fast and during hyperinsulinaemia.
MRI was used as anatomical reference. Obese participants were
studied again 6 months postoperatively.
Results In contrast to healthy individuals, insulin had no ef-
fect on intestinal GU in obese participants with or without
diabetes, suggesting that intestinal insulin resistance is present
early in morbid obesity. Postoperatively, jejunal GU increased
in line with whole-body and muscle GU. Postoperative GU
values in the intestine correlated with whole-body insulin
sensitivity, indicating that the intestinal mucosa may reflect
the overall glycaemic state and potentially mediate obesity-
associated insulin resistance.
Conclusions/interpretation This study shows that insulin is a
potent stimulator of GU in the healthy intestine and that intes-
tinal insulin resistance is ameliorated after bariatric surgery. In
our study, obese individuals had intestinal insulin resistance
regardless of their glycaemic status. Persistent changes in in-
testinal glucose metabolism are likely to influence both local
processes in the gut and systemic glucose homeostasis.
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Abbreviations
[18F]FDG Fluorine-18-labelled fluoro-deoxyglucose
GIP Glucose-dependent insulinotropic polypeptide
GLP-1 Glucagon-like peptide 1
GU Glucose uptake
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
Ki Fractional uptake rate
LC Lumped constant
MR(I) Magnetic resonance (imaging)
PET Positron emission tomography
PYY Pancreatic peptide YY3–36
RYGB Roux-en-Y gastric bypass
SG Sleeve gastrectomy
VOI Volumes of interest
Introduction
Understanding of the role of the intestine in glucose homeo-
stasis is progressing with the increasing adoption of bariatric
surgery in the management of morbid obesity. Bariatric
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surgery, originally intended to treat obesity, improves
glycaemic control and/or reverses diabetes [1]. Roux-en-Y
gastric bypass (RYGB), considered the standard technique,
involves creating a small gastric pouch using a surgical sta-
pler. This pouch is divided from the gastric remnant and anas-
tomosed to the jejunum, allowing ingested food to bypass
95% of the stomach, the duodenum and the first portions of
jejunum [1]. Alternatives to RYGB include sleeve gastrecto-
my (SG), in which a large portion of the stomach is removed
along the greater curvature [2].
In a systematic review, Meijer and others report a type 2
diabetes mellitus reversal rate of 83% in patients undergoing
the RYGB procedure [3]. Substantial weight loss occurs dur-
ing the postoperative weeks and months, but the main meta-
bolic changes occur rapidly and independently of weight loss
[4]. Both insulin secretion and the improvement of insulin
sensitivity are involved in the process. The increase in insulin
sensitivity is a major early postoperative outcome of RYGB,
whereas insulin secretion becomes affected at a later stage,
possibly as an adaptation to the weight loss [5]. As with any
intervention to treat diabetes, the residual beta cell function is
a strong predictor of remission after bariatric surgery [6].
The intestine is a large organ and is responsible for glucose
absorption. Among the mechanisms involved in the reversal
of diabetes after surgery, the role of the entero–insular axis
remains controversial [4, 7]. Two mechanisms are considered
mainly responsible for the early improvement in glucose con-
trol: an increase in hepatic insulin sensitivity following energy
restriction and an exaggerated secretion of glucagon-like pep-
tide 1 (GLP-1) due to a more rapid exposure of nutrients to the
distal jejunum [8].
Changes in the metabolic activity of the intestine after bar-
iatric surgery remain unclear. Quantitative studies in humans
are lacking, presumably because anatomical considerations
limit non-invasive access to the organ. Positron emission to-
mography (PET) is a unique method of measuring metabolic
rates in a specific tissue; the use of fluorine-18-labelled fluoro-
deoxyglucose ([18F]FDG) in quantitative studies has been val-
idated in several tissues and organs, such as the liver [9],
skeletal muscle [10] and brain [11]. [18F]FDG is transported
into cells, where it undergoes phosphorylation, but it cannot
be further metabolised, enabling its accumulation rate in spe-
cific regions to be measured. We have recently validated the
method to quantify intestinal glucose uptake (GU) against
autoradiography and tissue samples, and demonstrated that
within the intestine, most of the FDG accumulates in the mu-
cosal layer [12]. Using this method, we observed that the
intestinal mucosa is insulin resistant in human obesity. It is
not known whether insulin resistance of the intestinal mucosa
is reversed by bariatric surgery. The aim of this study was to
evaluate the effects of insulin on intestinal mucosal GU before
and after bariatric surgery in individuals with and without
diabetes.
Methods
Participants Morbidly obese individuals (n=21, age 47.3±
9.4 years, BMI 43.2±3.8 kg/m2), of whom eight had type 2
diabetes and five impaired fasting glucose (IFG) or impaired
glucose tolerance (IGT) according to current guidelines [13],
and age-matched healthy lean individuals (n=10, age 47.3±
6.0 years, BMI 23.7±1.8 kg/m2) were recruited (Table 1).
This study was part of the larger multicentre study
S l eevepa s s (C l i n i c a lTr i a l . gov r eg i s t r a t i on no .
NCT00793143), which is a randomised multicentre study
comparing two surgical techniques—RYGB and SG—in bar-
iatric surgery [2].
The obese participants recruited were consecutive patients
referred to the Turku University Hospital for bariatric surgery.
Inclusion criteria were BMI>40 kg/m2 or >35 kg/m2 with an
additional risk factor, age 18–60 years and a history of non-
successful carefully planned conservative treatments.
Individuals using insulin treatment and/or with mental disor-
ders, eating disorders, excessive use of alcohol or poor com-
pliance were excluded, as were those with a body weight over
150 kg, because of restrictions of the imaging devices. For
those with diabetes, the mean duration from onset was 3 years
and the condition was already well treated, as the mean HbA1c
was 6.3±0.3% (45.4 mmol/mol). All were using metformin.
One participant was additionally using pioglitazone and
sitagliptin, and one was using pioglitazone combined with
metformin. The participants with IGT or IFG were not using
any diabetes medication.
Healthy participants were recruited via an advertisement in
local newspapers. Theywere not obese and had normal OGTT
results.
Table 1 Anthropometric and metabolic characteristics of the study
participants
Characteristic Obese (n=21) Healthy (n=10)
Pre-operative Postoperative
Age (years) 47.3±9.4 47.3±6.0
Sex (M/F) 3/18 2/8
Type 2 diabetes 13
(2 IFG, 3 IGT)
6
(1 IFG, 1 IGT)
0
Weight (kg) 121±11 93±13*** 69±7***














FPG, fasting plasma glucose; M/F, male/female
*p<0.05, **p<0.01 and ***p<0.005 vs pre-operative values
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Written informed consent was obtained after explaining the
purpose and potential risks of the study to the individuals. The
study protocol was approved by the Ethics Committee of the
Hospital District of Southwest Finland and conducted accord-
ing to the principles of the Declaration of Helsinki.
Study design Obese individuals were stratified to undergo
RYGB or SG. The participants were imaged pre-operatively
in two PETsessions. Imaging was complementedwithMRI of
the whole body performed on separate days in order to obtain
an anatomical reference image. PET studies were performed
either after an overnight fast or during a euglycaemic–
hyperinsulinaemic clamp to study the stimulative effects of
insulin on regional glucose use. The same studies were done
in healthy individuals. Thereafter, obese participants followed
a diet very low in energy (very low calorie diet; VLCD) for
1 month before the operation. The maximal daily energy in-
take was restricted to 3.35 MJ (800 kcal). Bariatric surgery
was carried out and postoperative treatment administered ac-
cording to the clinical protocol [2]. At 6 months postopera-
tively, all the imaging and laboratory assessments were repeat-
ed to study intestinal metabolism after surgery.
PET studies Obese individuals underwent four PET sessions:
pre- and postoperative imaging studies were conducted both
during a euglycaemic–hyperinsulinaemic clamp and in the
fasting state. Participants were instructed to withhold from
glucose-lowering medications 24–72 h prior to the metabolic
studies. An overnight fast preceded all the imaging sessions.
Participants were lying in supine position during the PET
study. Two catheters were inserted: one in an antecubital vein
for the infusions of insulin and glucose and for tracer injection,
and the other in the opposite antecubital arterialised vein for
blood sampling.
Levels of blood glucose, HbA1c, incretins and hormones
were measured in all of the participants and again postopera-
tively in the obese participants. In studies using
hyperinsulinaemia, a euglycaemic–hyperinsulinaemic clamp
[14, 15] was started for 180 min using an intravenous insulin
infusion (1 mU kg−1 min−1; Actrapid, Novo Nordisk,
Copenhagen, Denmark). Euglycaemia was maintained using
variable rates of a 20% wt/vol. glucose infusion, adjusted ac-
cording to plasma glucose concentrations in arterialised blood,
as measured every 10 min. At an average of 90 min, after the
start of the study, [18F]FDG (mean 189 MBq, 147–218 MBq)
was injected over 15 s and a dynamic scan of the upper ab-
dominal region was started at 80 min (frames 5×180 s)
followed by a similar scan of the lower abdominal region at
100 min and the femoral region at 130 min (3×300 s)
(Fig. 1a). Arterial blood samples were drawn throughout the
Fig. 1 The imaging protocol and drawing of VOI. (a) In studies using
hyperinsulinaemia, a euglycaemic–hyperinsulinaemic clamp was started
for at least 180 min using intravenous insulin infusion. Euglycaemia was
maintained using variable rates of 20% wt/vol. glucose infusion. In
fasting studies, a 0.9% wt/vol. NaCl solution was used. At 90 min,
[18F]FDGwas injected and a dynamic scan of the upper abdominal region
was started at 170 min followed by lower abdominal region at 190 min
and femoral region at 220 min. (b) Axial slices of fused PET, MR images
and VOI of the duodenum of an obese participant pre- and postoperative-
ly. Luminal contents and highly active tissues were avoided in the anal-
ysis. VOI needed to be redrawn in the postoperative analysis because of
altered intestinal anatomy and reduced overall fat mass
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study after the [18F]FDG injection, and plasma radioactivity
was assessedwith an automatic gamma counter (Wizard 1480,
Wallac, Turku, Finland).
Image acquisition and processing [18F]FDG was synthesised
with an automatic apparatus as described by Hamacher et al
[16]. PET images were acquired using the PET scanner GE
Advance (General Electric Medical Systems, Milwaukee, WI,
USA), which has a transaxial resolution of 3.8 mm (full width
at half maximum [FWHM]) and slice width of 4.2 mm in the
centre of the imaging field [17]. A transmission scan of 5 min
was performed before the emission scan to correct for the
tissue attenuation of gamma photons. All image data were
corrected for dead time, decay and photon attenuation. MRI
was performed using a Philips Intera 1.5 T scanner (Best, the
Netherlands). The whole body of a participant was scanned
with axial in-and-out-of-phase images with a repetition time
of 120 ms, echo times of 2.3 ms and 4.63 ms, a slice thickness
of 10 mm and a matrix 530×530 mm2.
Analysis of PET images Regional GU in the intestine was
measured from the dynamic PET data using magnetic reso-
nance (MR) images as anatomical reference, as recently de-
scribed [12]. Localisation of the intestine was done on fused
PET and MR images and the final localisation was always
confirmed visually on the PET images. Both of the upper
and lower abdominal imaging regions were used to reliably
visualise and analyse parts of the intestine. Carimas 2.0.2 was
used to manually draw three-dimensional hollow tubular vol-
umes of interest (VOI) on sections of the descending duode-
num and the jejunum. An example of this is shown in Fig. 1b.
The tubular VOI were carefully shaped to contour the intesti-
nal wall, avoiding intestinal contents and external metaboli-
cally active organs. Because of the reduced fat mass and al-
tered gastrointestinal anatomy, VOI were redrawn in the post-
operative images. Care was taken to draw the jejunal VOI on a
section of the bowel distal to the Y-connection in the images of
patients who had undergone RYGB surgery. In some cases,
certain intestinal segments were not drawn and analysed be-
cause of uncertainty about the anatomy. Regions of interest
were drawn on femoral muscles to assess skeletal muscle GU,
as previously described [15].
A graphical method, the Gjedde–Patlak plot, was used to
analyse [18F]FDG kinetics [18]. The use of this method to
assess intestinal GU was validated in an animal model, in
which PET data were compared with ex vivo tissue activity
and autoradiography [12]. Regional time–activity curves
(TACs) were obtained from the VOI. A regional fractional
uptake rate (Ki) was then calculated using each regional
TAC and the plasma radioactivity curve. AVOI-specific GU
rate was calculated by multiplying Ki by corresponding plas-
ma glucose concentrations and dividing this product by a
lumped constant (LC) of 1.30 in fasting studies and 1.15 in
hyperinsulinaemic clamp studies [12]. An LC of 1.20 was
used in the femoral skeletal muscle analysis [10]. The LC
accounts for the differences in transport and phosphorylation
between D-glucose and FDG and is used to convert the FDG
uptake rate into the GU rate, expressed as μmol
glucose min−1 kg tissue−1. Whole-body GU was calculated
from the glucose infusion rate during PET in the
hyperinsulinaemic–euglycaemic clamp, and expressed also
in μmol min−1 kg−1.
Biochemical analysis Plasma glucose concentrations were
measured in duplicate using the glucose oxidase method
(Analox GM7 or GM9 Analox Instruments, London, UK).
The level of HbA1c was determined by HPLC (Variant II,
Bio-Rad, Hercules, CA, USA). The Milliplex MAP Human
Metabolic Hormone Panel was used to quantify the concen-
trations of active ghrelin, glucose-dependent insulinotropic
polypeptide (GIP) and pancreatic peptide YY3–36 (PYY) and
the Milliplex MAP Human Serum Adipokine Panel B was
used for measuring leptin concentrations, following manufac-
turer’s instructions (Millipore Corporation, Billerica, CA,
USA). The assay plates were analysed with Bio-Plex 200
System equipped with Bio-Plex Manager version 4.1 (Bio-
Rad Laboratories, Solna, Sweden). Minimum detection limits
for the active ghrelin, GIP, PYY and leptin were 2 pg/ml,
4 pg/ml, 7 pg/m and 85.4 pg/m, respectively.
Human GLP-1 and GLP-2 concentrations in lithium–hep-
arin plasma samples were measured using a sandwich ELISA
kit following the manufacturer’s instructions (Yanaihara
Institute, Shizuoka, Japan). The optical density of the samples
was determined using a Multiscan Ascent spectrophotometer
(Thermo Labsystems, Helsinki, Finland). The minimum de-
tection limits for the GLP-1 and GLP-2 assays were 0.206 and
0.412 ng/ml, respectively.
Statistical analysis Statistical analyses were performed using
the SAS software for Windows version 9.2 (SAS Institute,
Cary, NC, USA). Comparisons of non-paired data between
two groups were made using a Student’s t test. A paired t test
was used when comparing paired data. Pearson correlation
coefficients were calculated where appropriate. All data are
expressed as mean±SD. Values of p<0.05 were considered
significant.
Results
Metabolic characteristics Bariatric surgery resulted in a
marked weight loss and improvement in glycaemic control
(Table 1). Obese participants lost an average of 28 kg of
weight in the 6 months following the operation and insulin
sensitivity increased significantly, as shown by the whole-
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body GU rate (M value). The meanM value was increased by
an average of 80% but remained low compared with the
healthy participants (p<0.005). Type 2 diabetes was in full
remission—defined by normal plasma glucose in fasting con-
ditions and during the OGTT [13]—in three of the eight par-
ticipants with diabetes. Four participants still had diabetes and
one had IFG. Of the five participants with IFG or IGT pre-
operatively, four became euglycaemic and one developed di-
abetes. Metformin was still used by one participant. Diabetes
medication was otherwise not used. Mean postoperative
glycated haemoglobin was 5.9±0.3% (41 mmol/mol) in the
participants with a previous diagnosis of diabetes. There were
no differences in participants’ glycaemic status following the
two types of operation.
The effect of insulin on intestinal GU in healthy
participants Mean GU rates in the duodenum and jejunum
were low after an overnight fast in the healthy participants
(Fig. 2a) and in the same order of magnitude as in skeletal
muscle. Insulin stimulation doubled intestinal GU from circu-
lation (on average by 150% in the duodenum and 230% in the
jejunum, p<0.05 for both) (Fig. 2a). By comparison, skeletal
mu s c l e GU s h owed a 7 9 0% i n c r e a s e d u r i n g
hyperinsulinaemia (Fig. 2a).
Intestinal GU in obese participants Before the operation, in-
testinal and skeletal muscle GU under fasting conditions did
not differ from that in healthy participants (Fig. 2b). Obese
patients were insulin resistant at the whole-body level
(Table 1) and in line with this had blunted insulin-stimulated
skeletal muscle GU compared with healthy individuals
(Fig. 2b). The stimulatory effect of insulin on intestinal GU
seen in healthy participants was lacking in obese patients
(Fig. 2b). Jejunal GU tended to be associated with GU in
femoral muscle in the obese, but this was not statistically
significant (Fig. 3b). Correlations were also lacking in healthy
participants (Fig. 3a) and the duodenum. Neither the intestinal
nor the muscular GU differed between obese participants with
or without diabetes.
Effect of bariatric surgery on intestinal GU Analysis of the
studies performed 6 months postoperatively demonstrated no
significant changes in duodenal GU in either the fasting or the
hyperinsulinaemic state, compared with pre-operative values.
The duodenum was still insulin resistant with a mean increase
in GU during insulin stimulation of 39% (p=0.08). Compared
with the corresponding pre-operative values, jejunal GU was
increased postoperatively on average by 130% during fasting
(data not shown) and by 140% during hyperinsulinaemia (p=
0.049 and p=0.005, respectively) (Fig. 4). Whole-body insu-
lin sensitivity was significantly improved after the operation
but still remained low compared with healthy individuals
(Table 1). In line with this, muscle insulin-stimulated GU in-
creased by 180% compared with the pre-operative value
(p<0.001). Postoperatively, jejunal GU was significantly as-
sociated with femoral muscle GU (Fig. 3c). Glucose tolerance
was restored postoperatively in eight of the 13 participants
with diabetes, IGT or IFG. This, however, did not affect the
magnitude of increase observed in participants’ duodenal or
jejunal GU. A one-way ANOVA with diabetes remission as
the independent variable did not show a significant difference
in the absolute change in GU in each of the intestinal segments
between the glucose-tolerant and -intolerant participants who,
pre-operatively, were diabetic and obese.
No significant differences in the operation-induced chang-
es in intestinal GU were observed between the two surgical
procedures. As assessedwith a one-way ANOVA, the increase
in insulin-stimulated GU in the jejunum tended to be higher in
the participants who had undergone SG (13.0±11.2 vs 3.9±
6.7 μmol min−1 kg−1, p=0.055). Duodenal GU was
Fig. 2 GU in the intestine and skeletal muscle. (a) Intestinal and muscu-
lar GU in the fasting state (white bars) and during euglycaemic–
hyperinsulinaemia (black bars) in healthy participants. GU in both intes-
tinal segments was significantly stimulated by insulin. (b) As in (a), but
for the obese group (GU in fasting state, white bars; GU during
hyperinsulinaemia, black bars). Insulin sensitivity was lacking in the in-
testine, whereas GU in femoral muscle was still augmented by insulin.
*p<0.05
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unchanged with regard to the type of operation performed (p=
0.33). The use of metformin did not influence intestinal GU
before or after surgery.
Incretin and hormone levels Fasting levels of GLP-1 and
GLP-2 were similar between the obese and the healthy groups,
and did not change after bariatric surgery (Table 2). Mean
serum concentrations of GIP were 63% higher in obese par-
ticipants than in healthy ones, but this difference fell short of
statistical significance (p=0.055). Postoperatively, the con-
centrations of GIP in obese patients were decreased and sim-
ilar to the levels observed in healthy individuals (p=0.33). No
differences in PYYor ghrelin levels were present between the
groups. In obese patients, the mean leptin concentrations were
more than fourfold higher than in healthy participants at base-
line and decreased postoperatively (Table 2).
Whole-body insulin sensitivity was negatively associated
with the level of leptin (r=−0.74, p<0.005) pre-operatively.
No significant correlation was observed between pre-
operative regional GU rates and incretins or hormones.
Postoperatively, muscle GU in the fasting state correlated with
the level of ghrelin (r=0.89, p<0.01). This was not observed
during hyperinsulinaemia. No other significant correlations
between postoperative GU and cytokine levels were found.
Discussion
To our knowledge, these are the first results demonstrating
quantitative changes in the glucose metabolism of the intestine
in response to bariatric surgery in humans. Hyperinsulinaemia
does not enhance GU from the circulation in morbidly obese
insulin-resistant individuals, in contrast to its effects in healthy
individuals. This indicates insulin resistance of intestinal
enterocytes mucosa in the morbidly obese [12]. When obese
individuals were re-studied 6 months after the operation, a
small but significant improvement in jejunal, but not duode-
nal, glucose fluxes were observed.
Whether the difference in results is related to the type of
operation performed and consequent anatomical and metabol-
ic alterations or to the actual divergence in glucose metabo-
lism between the intestinal segments is not immediately evi-
dent. Our data failed to show a significant divergence in intes-
tinal GU between the two types of surgery, although jejunal
GU tended to be higher in the patients who underwent SG.
There are differences in the physiology of the duodenum
and jejunum. GLUT2 has been shown to be present in the
apical membrane of jejunal enterocytes of diabetic individuals
[19], and this has not been observed in duodenal biopsies [20].
Intestinal glucose absorption is largely regulated by changes
Fig. 3 Correlations between jejunal and femoral muscle GU. (a) Jejunal
GU did not correlate with the GU in femoral muscle in the healthy par-
ticipants (r=0.41, p=0.28). (b) In obese participants, jejunal and
muscular GU tended to correlate but failed to reach significance (r=
0.32, p=0.15). (c) After bariatric surgery, jejunal and muscular GU cor-
related more strongly (r=0.57, p<0.05)
Fig. 4 Effects of bariatric surgery on intestinal GU. Duodenal GU during
hyperinsulinaemia remained at the same level postoperatively (black
bars) as pre-operatively (white bars). Insulin-stimulated GU was in-
creased by an average of 140% in the jejunum after bariatric surgery.
*p<0.05
Table 2 Summary of the measured hormones and incretins
Hormone/incretin Obese (n=21) Healthy (n=10)
Pre-operative Postoperative
GLP-1 (ng/ml) 8.3±2.6 8.0±3.4 8.8±2.1
GLP-2 (ng/ml) 11.0±3.5 11.3±3.8 11.8±4.8
GIP (pg/ml)) 22.3±12.9 16.2±7.0† 13.6±6.1‡
PYY (ng/ml) 0.51±0.95 0.38±0.75 0.45±1.0
Leptin (ng/ml) 56.0±19.6 29.4±16.3*** 12.0±7.9***
Ghrelin (pg/ml) 38.2±33.3 34.8±42.4 54.4±51.9
***p<0.0001, † p=0.066 and ‡ p=0.055 vs pre-operative values
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in the location of GLUT2 in epithelial cells [21]. GLUT2 is
rapidly translocated to the brush border membrane in response
to dietary glucose. GLUT2 internalisation stimulated by insu-
lin is the limiting factor for GU from the intestine [21].
Insulin-resistant humans have GLUT2 in a permanently apical
location, which favours blood-to-lumen glucose flux during
fasting hyperglycaemia and remarkably high GU from the
lumen after a sugar-rich meal [19]. Our results support this
hypothesis. The obese individuals would present with a per-
manently apical GLUT2 leading to a pathological blood-to-
lumen glucose flux and decreased accumulation of glucose in
the enterocytes. Based on this, bariatric surgery would lead to
a healthier glucose metabolism in the jejunum by enabling the
insulin-inducible internalisation of GLUT2 which would thus
explain the higher postoperative jejunal GU. Duodenal GU
responds to insulin in healthy individuals. As GLUT2 is ab-
sent in the apical membrane of duodenal enterocytes, their
insulin-responsive glucose use is mediated by other pathways.
Intestinal gluconeogenesis is most likely one of the major
factors, as demonstrated by recent studies in mice and obese
humans. This diet-induced intestinal gluconeogenesis has
been proposed to mediate food intake and glucose homeosta-
sis (e.g. endogenous glucose production via portal glucose
sensing) [22, 23].
The main mechanisms suggested to account for early dia-
betes resolution after bariatric surgery include increased he-
patic insulin sensitivity due to energy restriction and improved
beta cell function. This is mainly a consequence of a more
substantial secretion of GLP-1 from the distal small intestine
[7]. Whether the increase in jejunal GU seen in our data di-
rectly promotes incretin secretion requires further study. In our
results, patients were stratified according the change (or lack
of change) in diagnostic category, from diabetes or IGT/IFG to
normal glucose tolerance, but no significant difference in the
respective changes in intestinal GU was found. The sample
size of these subgroups was insufficient to detect differences
based on categories. However, significant correlations were
seen between intestinal and femoral muscle GU after surgery,
which may indicate that intestinal insulin sensitivity helps
promote the resolution of diabetes in an indirect fashion (i.e.
via the improvement in whole-body GU). In our data, there
was no correlation between intestinal and muscle GU in the
healthy individuals, most probably because of the relatively
low number of participants and the small variation between
them.
PET is a highly sensitive method of quantitatively measur-
ing tissue-specific metabolic rates. We have recently validated
its use for the intestinal tract [12]. Some limitations still re-
main. The duodenum is fairly fixed in its location, but more
distal intestinal segments shift with changes in abdominal
pressure. This was addressed by selecting easily identifiable
vertical segments of the intestine and confirming the location
on PETand MRI while drawing VOI on the jejunum. Second,
the transaxial resolution of PET in conjunction with the thin-
ness of the intestinal wall might affect the results via two
phenomena, spillover and partial volume. However, these ef-
fects proved modest in our previous validation study [12]. In
the present study, the number of participants was relatively
small because of the demanding protocol and limited scanning
capacity. In addition, MR images from a separate day were
used as an anatomical reference, causing some variability in
anatomy between the imaging modalities. The obese individ-
uals had ameanweight of 121 kg. As the most morbidly obese
patients eligible for bariatric surgery were excluded, our re-
sults may have underestimated the metabolic effects of obesi-
ty. The participants were also already well treated with regard
to diabetes, which explains the small difference in glucose
levels between the obese and the healthy groups (Table 1).
However, participants were found to have variability in re-
gional and systemic insulin sensitivity.
In conclusion, this study shows that intestinal insulin resis-
tance is ameliorated after bariatric surgery. In our data, obese
individuals had intestinal insulin resistance regardless of their
glycaemic status, suggesting that intestinal insulin resistance
may occur before, and independently of, systemic insulin re-
sistance. The results highlight that insulin is a potent stimula-
tor of GU in the intestine, and that bariatric surgery induces
significant metabolic changes in the gut. It is likely that per-
sistent changes in intestinal glucose metabolism may have an
influence on both local processes in the gut and systemic
glucose homeostasis.
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